Terence Friedlander, MD

Articles

Dr Friedlander on the Design and Methods of the Duravelo-2 Trial in Urothelial Cancer

October 23rd 2024

Terence W. Friedlander, MD, discusses the design and methodology of the Duravelo-2 study of zelenectide pevedotin in advanced/metastatic urothelial cancer.

Dr Friedlander on Emerging Agents of Interest in Urothelial Cancer

October 17th 2024

Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.

Dr Friedlander on AEs Associated With Enfortumab Vedotin in Bladder Cancer

September 16th 2024

Terence W. Friedlander, MD, discusses adverse effects that are associated with standard enfortumab vedotin in bladder cancer.

Dr Friedlander on Updates in Frontline Bladder Cancer Management

September 9th 2024

Terence W. Friedlander, MD, discusses updates in the frontline management of bladder cancer.

Dr Friedlander on the Duravelo-2 Trial for Advanced or Metastatic Urothelial Cancer

August 8th 2024

Terence W. Friedlander, MD, discusses the investigation of BT8009 in the Duravelo-2 study in patients with advanced or metastatic urothelial cancer.

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

October 31st 2023

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Dr. Friedlander on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

April 3rd 2023

Terence Friedlander, MD, discusses the significance of the FDA approval of frontline enfortumab vedotin combined with pembrolizumab in patients with urothelial carcinoma.

Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

November 30th 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Dr. Friedlander on Checkpoint Inhibitors in Second-Line Bladder Cancer Treatment

October 31st 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.